The international epidemiology of lung cancer: Latest trends, disparities, and tumor characteristics

Journal of Thoracic Oncology

Volumn 11, Issue 10, 2016, Pages 1653-1671

  Cheng, Ting Yuan David ^a   Cramb, Susanna M ^b   Baade, Peter D ^b   Youlden, Danny R ^b   Nwogu, Chukwumere ^a   Reid, Mary E ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b CANCER COUNCIL QUEENSLAND   (Australia)

Author keywords

Disparity; Epidemiology; Histological type; International; Lung cancer; Survival

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR;

ADOLESCENT; ADULT; AFRICA; AGED; ARTICLE; AUSTRALIA; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CHINA; CLINICAL FEATURE; EARLY DIAGNOSIS; FEMALE; HEALTH CARE DISPARITY; HISTOLOGY; HUMAN; JAPAN; LIBYAN ARAB JAMAHIRIYA; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX RATIO; SMOKING; SOUTH AND CENTRAL AMERICA; SPAIN; SQUAMOUS CELL LUNG CARCINOMA; TREND STUDY; UNITED STATES; LUNG NEOPLASMS; TRENDS;

FEMALE; HEALTHCARE DISPARITIES; HUMANS; LUNG NEOPLASMS; MALE;

EID: 84991059360     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.05.021     Document Type: Article

References (163)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
2. Henley SJ, Richards TB, Underwood JM, Eheman CR, Plescia M, McAfee TA. Lung cancer incidence trends among men and women-United States, 2005-2009. MMWR Morb Mortal Wkly Rep. 2014;63:1-5.
3. Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS. US lung cancer trends by histologic type. Cancer. 2014;120:2883-2892.
4. Bosetti C, Malvezzi M, Rosso T, et al. Lung cancer mortality in European women: trends and predictions. Lung Cancer. 2012;78:171-178.
5. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374-1403.
6. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide. IARC CancerBase No. 11. http://globocan.iarc.fr. Accessed December 16, 2013.
7. United Nations Development Programme. Human Development Report 2013. The rise of the South: human progress in a diverse world. New York, NY: United Nations Development Programme; 2013.
8. Nishri ED, Sheppard AJ, Withrow DR, Marrett LD. Cancer survival among First Nations people of Ontario, Canada (1968-2007). Int J Cancer. 2015;136:639-645.
9. Sharp L, Brewster D. The epidemiology of lung cancer in Scotland: a review of trends in incidence, survival and mortality and prospects for prevention. Health Bull (Edinb). 1999;57:318-331.
10. Funatogawa I, Funatogawa T, Yano E. Trends in smoking and lung cancer mortality in Japan, by birth cohort, 1949-2010. Bull World Health Organ. 2013;91:332-340.
11. Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2012;10: 1236-1271.
12. Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD, Heath CW Jr. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst. 1997;89:1580-1586.
13. Samet JM, Avila-Tang E, Boffetta P, et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res. 2009;15:5626-5645.
14. Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol. 2008;3:819-831.
15. Forman D, Bray F, Brewster DH, et al., eds. Cancer incidence in five continents, Vol. X. http://www.iarc. fr/en/publications/pdfs-online/epi/sp164/. Accessed April 7, 2014.
16. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, eds. Pathology and Genetics of Tumours of the Lung, Pleura,Thymus and Heart. Lyon, France: IARC Press; 2004.
17. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon, France: IARC Press; 2015.
18. Ferlay J, Bray F, Steliarova-Foucher E, Forman D. Cancer Incidence in Five Continents, CI5plus: IARC CancerBase No. 9. http://ci5.iarc.fr/CI5plus/Default. aspx. Accessed September 24, 2014.
19. Australian Institute of Health and Welfare. Australian Cancer Incidence and Mortality. (ACIM) Books. http:// www.aihw.gov.au/acim-books/. Accessed November 24, 2014.
20. National Cancer Registry Ireland. The National Cancer Registry Ireland: incidence, mortality, treatment and survival. http://www.ncri.ie/. Accessed July 23, 2014.
21. Center for Cancer Control and Information Services, National Cancer Center Japan. Cancer incidence 1975-2010. Center for Cancer Control and Information Services, National Cancer Center. http://ganjoho.jp/en/ professional/statistics/table-download.html; Accessed April 17, 2014.
22. Netherlands Comprehensive Cancer Organisation (IKNL). Dutch cancer figures using Netherlands Cancer Registry data. http://www.cijfersoverkanker.nl/? languageen. Accessed December 3, 2014.
23. National Board of Health and Welfare (Socialstyrelsen). Cancer statistical database. http://www.socialstyrelsen. se/statistics/statisticaldatabase/cancer. Accessed April 9, 2013.
24. Hong Kong Cancer Registry. Cancer Statistics Query System by ICD-10. http://www3.ha.org.hk/cancereg/ e-a1b.asp. Accessed December 11, 2013.
25. Surveillance, Epidemiology, and End Results (SEER) Program. National Cancer Institute, DCCPS, Surveillance Research Program. Surveillance Systems Branch Research data (1973-2011). http://www.seer.cancer. gov. Released April 2014, based on the November 2013 submission; 2014.
26. World Health Organization. WHO Mortality Database (released 25 February 2014). http://www.who.int/ healthinfo/statistics/mortality-rawdata/en/. Accessed November 12, 2014.
27. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-E386.
28. Mathers CD, Fat DM, Inoue M, Rao C, Lopez AD. Counting the dead and what they died from: an assessment of the global status of cause of death data. Bull World Health Organ. 2005;83:171-177.
29. Segi M. Cancer mortality for selected sites in 24 countries (1950-57). Sendai, Japan: Department of Public Health, Tohoku University of Medicine; 1960.
30. Doll R, Payne P, Waterhouse JAH, eds. Cancer Incidence in Five Continents, Vol. I. Geneva, Switzerland: Union Internationale Contre le Cancer; 1966.
31. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385:977-1010.
32. Association of the Nordic Cancer Registries. Danish Cancer Society. NORDCAN: cancer incidence, mortality, prevalence and survival in the nordic countries, version 7.2 (16.12. 2015). http://www.ancr.nu. Accessed January 23, 2016.
33. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Database: Survival-SEER 18 Registries Research Data: National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014 (updated May 7, 2014), based on the November 2013 submission. http://seer. cancer.gov/data/seerstat/nov2013/. Accessed July 22, 2014.
34. Australian Institute of Health and Welfare. Cancer Survival and Prevalence in Australia: Period Estimates from 1982 to 2010 (Supplementary Material). Canberra, Australia: AIHW; 2012.
35. Lewis DR, Chen HS, Midthune DN, Cronin KA, Krapcho MF, Feuer EJ. Early estimates of SEER cancer incidence for 2012: approaches, opportunities, and cautions for obtaining preliminary estimates of cancer incidence. Cancer. 2015;121:2053-2062.
36. US Dept. of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2004.
37. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368:341-350.
38. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003;362:847-852.
39. Li Q, Hsia J, Yang G. Prevalence of smoking in China in 2010. N Engl J Med. 2011;364:2469-2470.
40. Parkin DM, Bray F, Ferlay J, Pisani P, Parkin DM. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
41. Saika K, Machii R. Cancer mortality attributable to tobacco by region based on the WHO Global Report. Jpn J Clin Oncol. 2012;42:771-772.
42. Thun M, Peto R, Boreham J, Lopez AD. Stages of the cigarette epidemic on entering its second century. Tob Control. 2012;21:96-101.
43. Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA. 2014;311:183-192.
44. Bray FI, Weiderpass E. Lung cancer mortality trends in 36 European countries: secular trends and birth cohort patterns by sex and region 1970-2007. Int J Cancer. 2010;126:1454-1466.
45. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ. 1997;315:980-988.
46. US Dept. of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2006.
47. National Cancer Institute. SEER stat fact sheets: lung and bronchus cancer. http://seer.cancer.gov/statfacts/ html/lungb.html. Accessed November 25, 2015.
48. McPhail S, Johnson S, Greenberg D, Peake M, Rous B. Stage at diagnosis and early mortality from cancer in England. Br J Cancer. 2015;112(suppl 1):S108-S115.
49. Meza R, Meernik C, Jeon J, Cote ML. Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. PLoS One. 2015;10:e0121323.
50. Stevens W, Stevens G, Kolbe J, Cox B. Lung cancer in New Zealand: patterns of secondary care and implications for survival. J Thorac Oncol. 2007;2:481-493.
51. Nadpara P, Madhavan SS, Tworek C. Guideline-concordant timely lung cancer care and prognosis among elderly patients in the United States: a population-based study. Cancer Epidemiol. 2015;39:1136-1144.
52. Higashi T, Nakamura F, Saruki N, Sobue T. Establishing a quality measurement system for cancer care in Japan. Jpn J Clin Oncol. 2013;43:225-232.
53. Takenaka T, Inamasu E, Yoshida T, et al. Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer. Surg Today. 2016;46:430-436.
54. Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, Bray F. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 2014;84:13-22.
55. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368:351-364.
56. Tse LA, Yu IT, Au JS, et al. Environmental tobacco smoke and lung cancer among Chinese nonsmoking males: might adenocarcinoma be the culprit? Am J Epidemiol. 2009;169:533-541.
57. Yu IT, Chiu YL, Au JS, Wong TW, Tang JL. Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women. Cancer Res. 2006;66:4961-4967.
58. Wang XR, Chiu YL, Qiu H, Au JS, Yu IT. The roles of smoking and cooking emissions in lung cancer risk among Chinese women in Hong Kong. Ann Oncol. 2009;20:746-751.
59. Ries LA. Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data.Semin Surg Oncol. 1994;10:21-30.
60. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101:3-27.
61. Pirker R, Herth FJ, Kerr KM, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010;5: 1706-1713.
62. Passiglia F, Caparica R, Giovannetti E, et al. The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer. Expert Opin Investig Drugs. 2016;25:385-392.
63. Farago AF, Le LP, Zheng Z, et al. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol. 2015;10:1670-1674.
64. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013;31:1039-1049.
65. Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol. 2015;16:e342-e351.
66. Chang JT, Lee YM, Huang RS. The impact of The Cancer Genome Atlas on lung cancer. Transl Res. 2015;166:568-585.
67. Wang R, Pan Y, Li C, et al. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. J Thorac Oncol. 2014;9:760-768.
68. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175-180.
69. Saber A, van der Wekkenb A, Hiltermannb TJN, Kokc K, van den Berga A, Groen HJM. Genomic aberrations guiding treatment of non-small cell lung cancer patients. Cancer Treat Commun. 2015;4:22-33.
70. Kohno T, Nakaoku T, Tsuta K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015;4:156-164.
71. Araujo LH, Lammers PE, Matthews-Smith V, et al. Somatic mutation spectrum of non-small-cell lung cancer in African Americans: A Pooled Analysis. J Thorac Oncol. 2015;10:1430-1436.
72. Heist RS, Sequist LV, Engelman JA. Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol. 2012;7:924-933.
73. Shames DS, Wistuba II. The evolving genomic classification of lung cancer. J Pathol. 2014;232:121-133.
74. McCormack VA, Schuz J. Africa's growing cancer burden: environmental and occupational contributions. Cancer Epidemiol. 2012;36:1-7.
75. Winkler V, Mangolo NJ, Becher H. Lung cancer in South Africa: a forecast to 2025 based on smoking prevalence data. BMJ Open. 2015;5:e006993.
76. Ng N, Winkler V, Van Minh H, Tesfaye F, Wall S, Becher H. Predicting lung cancer death in Africa and Asia: differences with WHO estimates. Cancer Causes Control. 2009;20:721-730.
77. World Health Organization. The global burden of disease: 2004 update. 2008 http://www.who.int/healthinfo/ global-burden-disease/2004-report-update/en/. Accessed July 13, 2015.
78. Chokunonga E, Levy LM, Bassett MT, Mauchaza BG, Thomas DB, Parkin DM. Cancer incidence in the African population of Harare, Zimbabwe: second results from the cancer registry 1993-1995. Int J Cancer. 2000;85:54-59.
79. Newton R, Ngilimana PJ, Grulich A, et al. Cancer in Rwanda. Int J Cancer. 1996;66:75-81.
80. Wabinga HR, Parkin DM,Wabwire-Mangen F, Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer. 2000;82:1585-1592.
81. Winkler V, Ott JJ, Cowan M, Becher H. Smoking prevalence and its impacts on lung cancer mortality in Sub-Saharan Africa: an epidemiological study. Prev Med. 2013;57:634-640.
82. Chatenoud L, Bertuccio P, Bosetti C, et al. Trends in mortality from major cancers in the Americas: 1980-2010. Ann Oncol. 2014;25:1843-1853.
83. Politis M, Higuera G, Chang LR, Gomez B, Bares J, Motta J. Trend analysis of cancer mortality and incidence in Panama, using joinpoint regression analysis. Medicine (Baltimore). 2015;94:e970.
84. Chatenoud L, Bertuccio P, Bosetti C, et al. Trends in cancer mortality in Brazil, 1980-2004. Eur J Cancer Prev. 2010;19:79-86.
85. Australian Institute of Health and Welfare. Cancer in Australia: An Overview, 2014. Canberra, Australia: Australian Institute of Health and Welfare; 2014.
86. Woodward SD. Trends in cigarette consumption in Australia. Aust N Z J Med. 1984;14:405-407.
87. Scollo MM, Winstanley MH. Tobacco in Australia: Facts and Issues. Melbourne, Australia: Cancer Council Victoria; 2012.
88. Gray NJ, Hill DJ. Patterns of tobacco smoking in Australia.2. Med J Aust. 1977;2:327-328.
89. Hill DJ, White VM, Scollo MM. Smoking behaviours of Australian adults in 1995: trends and concerns. Med J Aust. 1998;168:209-213.
90. White V, Hill D, Siahpush M, Bobevski I. How has the prevalence of cigarette smoking changed among Australian adults? Trends in smoking prevalence between 1980 and 2001. Tob Control. 2003;12:ii67-ii74.
91. US Department of Health, Education, and Welfare. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC: US Department of Health, Education, and Welfare, Public Health Service; 1964. Public Health Service Publication No. 1103.
92. Smith CN, Kraemer JD, Johnson AC, Mays D. Plain packaging of cigarettes: do we have sufficient evidence? Risk Manag Healthc Policy. 2015;8:21-30.
93. World Health Organization. WHO Framework Convention on Tobacco Control. A56/8. Geneva, Switzerland: WHO; 2003.
94. Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014;26:48-58.
95. Chen WQ, Zheng RS, Zhang SW, et al. Report of incidence and mortality in china cancer registries, 2008. Chin J Cancer Res. 2012;24:171-180.
96. Chen W, Zheng R, Zhang S, et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 2013;25:10-21.
97. Chen W, Zheng R, Zeng H, Zhang S, He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res. 2015;27:2-12.
98. Chen W, Zheng R, Zeng H, Zhang S. Epidemiology of lung cancer in China. Thorac Cancer. 2015;6:209-215.
99. She J, Yang P, Hong Q, Bai C. Lung cancer in China: challenges and interventions. Chest. 2013;143:1117-1126.
100. Zou XN, Lin DM, Wan X, et al. Histological subtypes of lung cancer in Chinese males from 2000 to 2012. Biomed Environ Sci. 2014;27:3-9.
101. Zhang L, Li M, Wu N, Chen Y. Time trends in epidemiologic characteristics and imaging features of lung adenocarcinoma: a population study of 21,113 cases in China. PLoS One. 2015;10:e0136727.
102. Liu BQ, Peto R, Chen ZM, et al. Emerging tobacco hazards in China:1 Retrospective proportional mortality study of one million deaths. BMJ. 1998;317: 1411-1422.
103. Yang L, Parkin DM, Li L, Chen Y. Time trends in cancer mortality in China: 1987-1999. Int J Cancer. 2003;106:771-783.
104. Hu TW, Mao Z, Shi J, Chen W. The role of taxation in tobacco control and its potential economic impact in China. Tob Control. 2010;19:58-64.
105. Wang CP, Ma SJ, Xu XF, Wang JF, Mei CZ, Yang GH. The prevalence of household second-hand smoke exposure and its correlated factors in six counties of China. Tob Control. 2009;18:121-126.
106. Abdullah AS, Qiming F, Pun V, Stillman FA, Samet JM. A review of tobacco smoking and smoking cessation practices among physicians in China: 1987-2010. Tob Control. 2013;22:9-14.
107. Smith DR, Zhao I, Wang L. Tobacco smoking among doctors in mainland China: a study from Shandong province and review of the literature. Tob Induc Dis. 2012;10:14.
108. Yang Y, Wang JJ, Wang CX, Li Q, Yang GH. Awareness of tobacco-related health hazards among adults in China. Biomed Environ Sci. 2010;23:437-444.
109. Hu TW, Lee AH, Mao Z. WHO Framework Convention on Tobacco Control in China: barriers, challenges and recommendations. Glob Health Promot. 2013;20:13-22.
110. Giovino GA, Mirza SA, Samet JM, et al. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. Lancet. 2012;380:668-679.
111. Feng G, Jiang Y, Zhao L, et al. [Degree of exposure to secondhand smoking and related knowledge, attitude among adults in urban China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2014;35:998-1001 [in Chinese].
112. Ye X, Yao Z, Gao Y, et al. Second-hand smoke exposure in different types of venues: before and after the implementation of smoke-free legislation in Guangzhou, China. BMJ Open. 2014;4:e004273.
113. Zhang JJ, Smith KR. Household air pollution from coal and biomass fuels in China: measurements, health impacts, and interventions. Environ Health Perspect. 2007;115:848-855.
114. Zhang J,Mauzerall DL, Zhu T, Liang S, EzzatiM, Remais JV. Environmental health in China: progress towards clean air and safe water. Lancet. 2010;375:1110-1119.
115. Niu SR, Yang GH, Chen ZM, et al. Emerging tobacco hazards in China: 2 Early mortality results from a prospective study. BMJ. 1998;317:1423-1424.
116. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
117. Burns DM, Lee L, Shen LZ, Gilpin E, Tolley HD, Vaughn J, et al. Cigarette smoking behavior in the United States. In: Tobacco Control Monograph Series Monograph 8: Changes in Cigarette-Related Disease Risks and Their Implications for Prevention and Control. Bethesda, MD: National Cancer Institute; 1997.
118. US Centers for Disease Control and Prevention. Great American Smokeout-November 18, 1999. MMWR: Morb Mortal Wkly Rep. 1999;48:985-993.
119. US Centers for Disease Control and Prevention. Current cigarette smoking among adults-United States, 2011. MMWR: Morb Mortal Wkly Rep. 2012;61:889-894.
120. Moolgavkar SH, Holford TR, Levy DT, et al. Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst. 2012;104:541-548.
121. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
122. US Centers for Disease Contro and Prevention. Tobacco control state highlights 2012. http://www.cdc.gov/tobacco/ data-statistics/state-data/state-highlights/2012/. Accessed December 11, 2015.
123. Jemal A, Ma J, Rosenberg PS, Siegel R, Anderson WF. Increasing lung cancer death rates among young women in southern and midwestern States. J Clin Oncol. 2012;30:2739-2744.
124. Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med. 2006;354:333-342.
125. Brooks DR, Palmer JR, Strom BL, Rosenberg L. Menthol cigarettes and risk of lung cancer. Am J Epidemiol. 2003;158:609-616 [discussion 617-620].
126. Sidney S, Tekawa IS, Friedman GD, Sadler MC, Tashkin DP. Mentholated cigarette use and lung cancer. Arch Intern Med. 1995;155:727-732.
127. Carpenter CL, Jarvik ME, Morgenstern H, McCarthy WJ, London SJ. Mentholated cigarette smoking and lungcancer risk. Ann Epidemiol. 1999;9:114-120.
128. Kabat GC, Hebert JR. Use of mentholated cigarettes and lung cancer risk. Cancer Res. 1991;51:6510-6513.
129. Richardson TL. African-American smokers and cancers of the lung and of the upper respiratory and digestive tracts. Is menthol part of the puzzle? West J Med. 1997;166:189-194.
130. Kabat GC, Shivappa N, Hebert JR. Mentholated cigarettes and smoking-related cancers revisited: an ecologic examination. Regul Toxicol Pharmacol. 2012;63:132-139.
131. Raz DJ, Gomez SL, Chang ET, et al. Epidemiology of nonsmall cell lung cancer in Asian Americans: incidence patterns among six subgroups by nativity. J Thorac Oncol. 2008;3:1391-1397.
132. Epplein M, Schwartz SM, Potter JD, Weiss NS. Smokingadjusted lung cancer incidence among Asian-Americans (United States). Cancer Causes Control. 2005;16:1085-1090.
133. Ezzati M, Henley SJ, Lopez AD, Thun MJ. Role of smoking in global and regional cancer epidemiology: current patterns and data needs. Int J Cancer. 2005;116:963-971.
134. Rogers T. The California Tobacco Control Program: introduction to the 20-year retrospective. Tob Control. 2010;19 Suppl 1:i1-i2.
135. Au JS, Mang OW, Foo W, Law SC. Time trends of lung cancer incidence by histologic types and smoking prevalence in Hong Kong 1983-2000. Lung Cancer. 2004;45:143-152.
136. Linares I,Molina-Portillo E, Exposito J, Baeyens JA, Suarez C, Sanchez MJ. Trends in lung cancer incidence by histologic subtypeinthesouthofSpain,1985-2012:apopulation-based study. Clin Transl Oncol. 2015;18:489-496.
137. Vanthomme K, Vandenheede H, Hagedoorn P, Deboosere P, Gadeyne S. Trends in site-and sex-specific cancer mortality between 1979 and 2010 in Belgium compared with Europe using WHO data. J Public Health (Oxf). 2016;38:e70-e76.
138. Olajide OO, Field JK, Davies MM, Marcus MW. Lung cancer trend in England for the period of 2002 to 2011 and projections of future burden until 2020. Int J Oncol. 2015;47:739-746.
139. Paskett ED, Bernardo BM, Khuri FR. Tobacco and China: The worst is yet to come. Cancer. 2015;121(suppl 17):3052-3054.
140. Wong CM, Vichit-Vadakan N, Vajanapoom N, et al. Part 5 Public health and air pollution in Asia (PAPA): a combined analysis of four studies of air pollution and mortality. Res Rep Health Eff Inst. 2010:377-418.
141. McCarthy WJ, Meza R, Jeon J, Moolgavkar SH. Chapter 6: Lung cancer in never smokers: epidemiology and risk prediction models. Risk Anal. 2012;32(suppl 1):S69-S84.
142. Mc Laughlin J. An historical overview of radon and its progeny: applications and health effects. Radiat Prot Dosimetry. 2012;152:2-8.
143. Shen J, Liao J, Guarnera MA, et al. Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis. J Thorac Oncol. 2014;9:33-40.
144. Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol. 2014;32:768-773.
145. Spira A, Halmos B, Powell CA. Update in lung cancer 2014. Am J Respir Crit Care Med. 2015;192:283-294.
146. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
147. Wood DE, Kazerooni E, Baum SL, et al. Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2015;13:23-34 [quiz 34].
148. US Centers for Disease, Control, Prevention. Cancer screening-United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61:41-45.
149. Kiviniemi MT, Bennett A, Zaiter M, Marshall JR. Individual-level factors in colorectal cancer screening: a review of the literature on the relation of individuallevel health behavior constructs and screening behavior. Psychooncology. 2011;20:1023-1033.
150. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014;371:1793-1802.
151. Cokkinides V, Bandi P, Ward E, Jemal A, Thun M. Progress and opportunities in tobacco control. CA Cancer J Clin. 2006;56:135-142.
152. Tanner NT, Kanodra NM, Gebregziabher M, et al. The association between smoking abstinence and mortality in the National Lung Screening Trial. Am J Respir Crit Care Med. 2016;193:534-541.
153. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ. 2010;340: b5569.
154. Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw. 2014;12:1738-1761.
155. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382:709-719.
156. Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw. 2015;13:515-524.
157. Califano R, Abidin A, Tariq NU, Economopoulou P, Metro G, Mountzios G. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. Cancer Treat Rev. 2015;41:401-411.
158. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8:823-859.
159. Xue C, Hu Z, Jiang W, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer. 2012;77:371-375.
160. Hagemann IS, Devarakonda S, Lockwood CM, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer. 2015;121:631-639.
161. Davies M. New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res. 2014;6:63-75.
162. Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121:664-672.
163. Morabito A, Carillio G, Daniele G, et al. Treatment of small cell lung cancer. Crit Rev Oncol Hematol. 2014;91:257-270.